Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis

Author:

Park Sun Jun123,Yeon Seul Ki1,Kim Yoowon14,Kim Hyeon Jeong14,Kim Siwon12,Kim Jushin14,Choi Ji Won1,Kim Byungeun12,Lee Elijah Hwejin12,Kim Rium12,Seo Seon Hee1,Lee Jaeick5ORCID,Kim Jun Woo6,Lee Ha-Yeon6,Hwang Hayoung6,Bahn Yong-Sun4,Cheong Eunji4,Park Jong-Hyun12,Park Ki Duk12ORCID

Affiliation:

1. Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea

2. Division of Bio-Med Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Republic of Korea

3. Cureverse Co., Ltd., KIST, 1st Floor, H2 Building, Seoul 02792, Republic of Korea

4. Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea

5. Doping Control Center, KIST, Seoul 02792, Republic of Korea

6. New Drug Development Center, Daegu Gyeongbuk Medical Innovation Foundation (DGMIF), Daegu 41061, Republic of Korea

Funder

National Research Foundation of Korea

Korea Institute of Science and Technology

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3